SAN DIEGO, March 14, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present nonclinical data from six studies at the 109th annual meeting of the American Association of Cancer Research…
